Drug Profile
Nitroxoline - Asieris Pharmaceuticals
Alternative Names: APL-1202; VesiqueLatest Information Update: 02 Feb 2024
Price :
$50
*
At a glance
- Originator Johns Hopkins University
- Developer Asieris Pharmaceuticals
- Class Antibacterials; Antifungals; Antineoplastics; Hydroxyquinolines; Quinolones; Small molecules
- Mechanism of Action Methionine aminopeptidase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Bladder cancer
- No development reported Prostate cancer
Most Recent Events
- 29 Jan 2024 Efficacy and adverse events data from the phase I/II ANTICIPATE trial in Bladder cancer released by Asieris Pharmaceuticals
- 25 Jan 2024 Efficacy and adverse events data from phase-I/II ANTICIPATE trail in Bladder cancer (Neoadjuvant therapy, Combination therapy) presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium(ASCO-GeCS-2024)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Bladder-cancer(Combination therapy, In volunteers) in Australia (PO, Tablet)